Wajeeha Elahi, Ameen Zubair Syed, Bhagwan Das, Bella Dayo, Rafia Memon, Afreen Naz.
To compare the efficacy of febuxostatversus allopurinol in patients with hyperuricemia due to kidney disease.
Pak J Med Health Sci Jan ;13(4):942-4.

Aim : To determine the efficacy of febuxostat versus Allopurinol in reducing level of serum uric acid among patients of hyperuricemia due to chronic kidney disease. Study design : This Randomized Control Trials study was conducted at the Nephrology department (OPD), Jinnah Postgraduate Medical Centre, Karachi. All the patients of stage 3 and 4 chronic kidney disease and uric acid level > 6.8mg / dl were selected. Patients were divided in tow groups. Patients of group A underwent oral administration of febuxostat 240mg/day and patients of group B underwent allopurinol 100mg/day for 26 weeks. Patients were followed for 24 weeks and serum uric acid level was done. The efficacy was labeled as positive, in participants achieving serum uric acid <6.0mg/dl after 24 weeks of trial. Results : Mean age of the patients was 51.57±20.38 years. Gender distribution shows that 54(77.1%) patients were male while 16 (22.9%) patients were female. Out of total 35 patients in febuxostat group, efficacy was found in 23 (65.7%) patients and among 35 patients of allopurinol group, efficacy was found in 15 (39.5%) patients. Chi - square test was applied to compare the efficacy in both of the two groups and a significant difference was found (p- 0.055). Conclusion : It was concluded that efficacy of febuxostat was higher than Allopurinol in lowering the serum uric acid levels in patients with hyperuricemia due to chronic kidney disease.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com